May 17, 2024

Biologics License Application

Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) RYBREVANT FDA Submission
2 min read

Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S....
Read More

You may have missed

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH HCAH PMR Services
3 min read

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

May 15, 2024
1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY IVF Treatments for Infertility
2 min read

1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY

May 14, 2024
Exactech Enhances High Technology Knee System with New Balancing Software Exactech Ligament-Driven Balancing TechnologyExactech Ligament-Driven Balancing Technology
2 min read

Exactech Enhances High Technology Knee System with New Balancing Software

May 13, 2024
BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000 BGI-Heilongjiang Omics Health Axis Intelligent Laboratory
2 min read

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

May 13, 2024